Orchid Pharma inks tech transfer pact with biotechnology firm for 7ACA project.

Orchid Pharma Ltd. recently announced that it has entered into a technology transfer agreement with a leading multinational biotechnology company for its fermentation based ‘7ACA project’ under the production linked incentive (PLI) scheme. 

The Chennai-based pharmaceutical manufacturer, however, did not disclose the name of the biotechnology firm or further details of the agreement.

In July last year, Orchid Pharma announced that its wholly-owned subsidiary, Orchid Bio Pharma, has received approval to manufacture ‘7-ACA’ product with a committed capacity of 1,000 tonne per annum. 7-ACA (7-aminocephalosporanic acid) is the core chemical structure for the synthesis of cephalosporin antibiotics and intermediates. 

Subsequently, Orchid Bio Pharma entered into an MoU with an overseas technology provider for in-licensing of 7ACA. The company also announced an investment of ₹600 crore in capex towards its upcoming new manufacturing plant in Jammu set up under PLI scheme. 

HBL